Oxford Asset Management LLP Buys New Shares in Amgen Inc. (NASDAQ:AMGN)

Oxford Asset Management LLP bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,790 shares of the medical research company's stock, valued at approximately $1,248,000. Amgen accounts for approximately 0.6% of Oxford Asset Management LLP's holdings, making the stock its 25th biggest position.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Centricity Wealth Management LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $25,000. Ritter Daniher Financial Advisory LLC DE raised its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC purchased a new position in Amgen in the 4th quarter valued at $34,000. Atala Financial Inc purchased a new position in shares of Amgen in the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company's stock.

Analysts Set New Price Targets

AMGN has been the subject of a number of analyst reports. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 17th. Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Morgan Stanley lifted their price target on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 9th. Royal Bank of Canada reissued an "outperform" rating and issued a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Finally, Piper Sandler Companies reiterated an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $310.57.

Amgen Stock Up 0.8 %

Amgen stock traded up $2.36 during mid-day trading on Wednesday, hitting $290.92. The company had a trading volume of 2,607,155 shares, compared to its average volume of 3,145,816. The business has a fifty day moving average of $301.10 and a 200 day moving average of $292.08. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a market cap of $156.41 billion, a price-to-earnings ratio of 38.53, a PEG ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.